Doctors Can Be Misled About FDA 'Breakthrough' Drug Designation

Share this content:
Doctors Can Be Misled About FDA 'Breakthrough' Drug Designation
Doctors Can Be Misled About FDA 'Breakthrough' Drug Designation

TUESDAY, April 12, 2016 (HealthDay News) -- Use of the word "breakthrough" in the U.S. Food and Drug Administration's expedited approval process could mislead doctors about the new drugs' actual benefits, according to a research letter published in the April 12 issue of the Journal of the American Medical Association.

The U.S. Congress in 2012 gave FDA the power to designate a drug as a "breakthrough therapy" if preliminary clinical evidence suggests an advantage over existing medications. But a survey of 692 doctors revealed that many tended to misinterpret "breakthrough." Doctors often believed the drugs were supported by stronger evidence than the law requires to achieve that designation, lead author Aaron Kesselheim, M.D., J.D., M.P.H., a faculty member at Brigham and Women's Hospital in Boston, told HealthDay.

In the survey, nine out of 10 doctors chose one hypothetical drug over another identical one solely based on the "breakthrough" designation, even though both were taken on the same schedule, had similar side effects, and were equally covered by the patient's insurance. In addition, 52 percent incorrectly believed that strong evidence from randomized trials is needed to earn the breakthrough designation. The survey also revealed a widespread lack of understanding about the meaning of FDA approval for a new drug, the researchers reported.

The FDA released the following statement in response to the study: "In general, the FDA does not comment on specific studies, but evaluates them as part of the body of evidence to further our understanding about a particular issue and assist in our mission to protect public health."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »